Talha Badar, Hematology/Oncology Specialist at Mayo Clinic, shared a post on X about a paper he co-authored with colleagues published in Leukemia Research:
“Applicability of current prognostication models for MDS patients with DDX41 mutation.
Led by Aref Al-Kali.
Current prognostic scoring systems – IPSS, IPSS-R, and IPSS-M – may not reliably predict overall survival in patients with DDX41-mutated myelodysplastic syndromes.
However, a simplified version of IPSS-M (with two broader risk groups) may still offer prognostic value.
Interestingly, patients with normal platelet counts showed a potential survival advantage, suggesting platelet status could be a useful marker in this subgroup.
Further studies with larger cohorts are needed to validate these findings and refine risk assessment for DDX41-mutated MDS.”
Title: Applicability of current prognostication models for MDS patients with DDX41 mutation
Authors: Nadia Toumeh, Yazan Jabban, Rong He, David Viswanatha, Dragan Jevremovic, Patricia T. Greipp, James M. Foran, Talha Badar, Cecilia Y. Arana Yi, Yael Kusne, Antoine N. Saliba, Mehrdad Hefazi Thorghabeh, Aasiya Matin, William J. Hogan, Mithun V. Shah, Abhishek A. Mangaonkar, Mrinal M. Patnaik, Hassan B. Alkhateeb, and Aref Al-Kali
You can read the Full Article in Leukemia Research.
More posts featuring Talha Badar.